Menu Search
Equities

Medlab Clinical Ltd

MDC:ASX

Medlab Clinical Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)6.60
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta1.7090
Data delayed at least 20 minutes, as of Feb 22 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Medlab Clinical Ltd had revenues fall -28.90% from 1.33m to 943.67k, though the company grew net income from a loss of 7.16m to a smaller loss of 6.78m.
Gross margin84.77%
Net profit margin-970.74%
Operating margin-1,195.93%
Return on assets-103.72%
Return on equity-308.75%
Return on investment-240.52%
More ▼

Cash flow in AUDView more

In 2023, cash reserves at Medlab Clinical Ltd fell by 4.97m. However, Cash Flow from Investing totalled 982.77k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 5.47m for operations while cash used for financing totalled 481.55k.
Cash flow per share-1.44
Price/Cash flow per share--
Book value per share-0.3068
Tangible book value per share-0.3068
More ▼

Balance sheet in AUDView more

Medlab Clinical Ltd uses little or no debt in its capital structure.
Current ratio0.35
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.